PASI (Psoriasis Area and Severity Index)
Immunology· appears in 400+ cited findings in this library
What it is and how the reviews use it
PASI (Psoriasis Area and Severity Index) is a rating scale used in regulatory review documents to assess the severity and extent of psoriasis. It functions as an endpoint in clinical trials, with various response rates (e.g., PASI 75, PASI 90, PASI 100) frequently reported. These response rates indicate the percentage reduction in the PASI score from baseline, signifying improvement in a patient's condition.
Regulatory reviews in this library utilize PASI to evaluate the efficacy of treatments for psoriasis. For instance, Bristol-Myers Squibb Company's Sotyktu showed a PASI 100 at Week 16 of 3.0%. UCB SA's Bimzelx reported a PASI-90 response rate (%) of 0. Almirall S A's Ilumetri demonstrated a PASI 75 response rate of 62.3%.
Real examples — cited to the source page
| Sotyktu | PASI 100 at Week 16 | 3.0% | Bristol-Myers Squibb Company — Sotyktu EMA EPAR public assessment repo, p.113 |
| Bimzelx | PASI-90 response rate (%) | 0 | UCB SA — Bimzelx FDA Review (BLA761151, ORIG 1, 2023), p.269 |
| Tremfya | Median time to loss of PASI 90 | 15 weeks | Johnson & Johnson — Tremfya FDA Review (BLA761061, ORIG 1, 2017), p.120 |
| Ilumetri | PASI 75 response rate | 62.3 % | Almirall S A — Ilumetri EMA EPAR public assessment report (EMEA/H/C/00, p.66 |
| Kyntheum | PASI 75 responders (%) | 60.3 % | LEO A S — Kyntheum EMA EPAR public assessment report (EMEA/H/C/003959,, p.95 |
| Skilarence | PASI 75 response rate | 40.3 % | Almirall S A — Skilarence EMA EPAR public assessment report (EMEA/H/C/, p.60 |
| Taltz | Mean baseline PASI | 20 | Eli Lilly and Company — Taltz FDA Review (BLA125521, ORIG 1, 2016), p.100 |
Different drugs were studied in different trials — these values are not head-to-head comparisons.
Explore the full evidence
Every PASI finding in the library — searchable and answerable in plain language — is in the Immunology research library →
Figures are as stated in the cited source documents. Educational reference only — not medical or investment advice.